超富美少女 personal page - To The Moon

超富美少女

超富美少女

萌新一枚，来社区记录2021交易情况

874Follow

139Followers

0Topic

0Badge

超富美少女

2022-10-05

KKK

@FinMelon:微波消融醫療器械提供商百德醫療迎年均增速33%的行業性機遇

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3559265417743172","uuid":"3559265417743172","gmtCreate":1596183077894,"gmtModify":1611383356553,"name":"超富美少女","pinyin":"cfmsnchaofumeishaonv","introduction":"","introductionEn":null,"signature":"萌新一枚，来社区记录2021交易情况","avatar":"https://static.tigerbbs.com/7392e7e668ef54b7632379da408c4140","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":139,"headSize":874,"tweetSize":550,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":3,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.25","exceedPercentage":"60.62%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[],"hots":[{"id":668584087,"gmtCreate":1664941966453,"gmtModify":1676537533731,"author":{"id":"3559265417743172","authorId":"3559265417743172","name":"超富美少女","avatar":"https://static.tigerbbs.com/7392e7e668ef54b7632379da408c4140","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559265417743172","authorIdStr":"3559265417743172"},"themes":[],"htmlText":"KKK","listText":"KKK","text":"KKK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/668584087","repostId":"661416943","repostType":1,"repost":{"id":661416943,"gmtCreate":1664181812586,"gmtModify":1676537404666,"author":{"id":"3494295154959832","authorId":"3494295154959832","name":"FinMelon","avatar":"https://static.tigerbbs.com/eef68a536f68680437ea6627d1d64b6e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3494295154959832","authorIdStr":"3494295154959832"},"themes":[],"title":"微波消融醫療器械提供商百德醫療 迎年均增速33%的行業性機遇","htmlText":"微波消融醫療器械龍頭企業百德醫療，即將完成IPO最後衝刺。2022年9月22日，百德醫療（6678.HK）公告稱公司在香港資本市場開啓招股環節，保薦機構爲中泰國際融資、中銀國際亞洲。公司此次IPO預計發行2.48億股，其中香港公開發售2480萬股，國際發售2.23億股，超額配售最多爲3720萬股（如有）。發行價格區間爲每股1.40至1.72港元。預計上市日期爲2022年10月5日，每手2000股。募集資金中41%將用作擴大及深化公司的產品組合、升級公司的醫療許可證及擴充研發團隊；38%將用作選擇性尋求能夠補充公司的現有產品組合、銷售及分銷網絡、技術，併爲公司的業務增長創造協同效應的策略收購、投資或業務協同合作機會；8%將用作透過設立海外辦事處；3%將用於購買自動化機械及設備以提高公司的生產線的自動化水平；10%將用作額外營運資金及其他一般公司用途。目前看來，作爲國內市場上首家有甲狀腺3類證企業，公司已成爲微波消融醫療器械領先供應商之一，按2021年微波消融針的銷售收入及銷量計，更是中國治療甲狀腺結節及乳腺結節的微波消融醫療器械第一大龍頭，規模、技術優勢背景下公司近年來業績不斷增長。未來，隨着行業規模高速增長以及公司與機構合作的研發模式保證產品線穩定擴張，百德醫療有望持續展現高增長態勢。深耕微波消融 成就領域大龍頭地位十餘年專注，百德醫療已經成爲行業的龍頭型企業。微波消融是一種微創治療技術，利用微波能量產生的極高熱量改變腫瘤細胞蛋白質的性質，並使其凝結。微波消融治療已應用於不同的良性及惡性腫瘤並具有安全、微創、操作簡便、患者恢復快及併發症低等優點。部分類型的良性腫瘤可能通過稱爲癌症進展的過程轉變爲惡性腫瘤。根據弗若斯特沙利文資料，肺結節、甲狀腺結節及乳腺結節患者的癌症進展率分別爲5.5%、5.0%和7.0%。微波消融治療可以通過抑制良性腫瘤發展爲惡性腫瘤來阻止癌症進展。成立於","listText":"微波消融醫療器械龍頭企業百德醫療，即將完成IPO最後衝刺。2022年9月22日，百德醫療（6678.HK）公告稱公司在香港資本市場開啓招股環節，保薦機構爲中泰國際融資、中銀國際亞洲。公司此次IPO預計發行2.48億股，其中香港公開發售2480萬股，國際發售2.23億股，超額配售最多爲3720萬股（如有）。發行價格區間爲每股1.40至1.72港元。預計上市日期爲2022年10月5日，每手2000股。募集資金中41%將用作擴大及深化公司的產品組合、升級公司的醫療許可證及擴充研發團隊；38%將用作選擇性尋求能夠補充公司的現有產品組合、銷售及分銷網絡、技術，併爲公司的業務增長創造協同效應的策略收購、投資或業務協同合作機會；8%將用作透過設立海外辦事處；3%將用於購買自動化機械及設備以提高公司的生產線的自動化水平；10%將用作額外營運資金及其他一般公司用途。目前看來，作爲國內市場上首家有甲狀腺3類證企業，公司已成爲微波消融醫療器械領先供應商之一，按2021年微波消融針的銷售收入及銷量計，更是中國治療甲狀腺結節及乳腺結節的微波消融醫療器械第一大龍頭，規模、技術優勢背景下公司近年來業績不斷增長。未來，隨着行業規模高速增長以及公司與機構合作的研發模式保證產品線穩定擴張，百德醫療有望持續展現高增長態勢。深耕微波消融 成就領域大龍頭地位十餘年專注，百德醫療已經成爲行業的龍頭型企業。微波消融是一種微創治療技術，利用微波能量產生的極高熱量改變腫瘤細胞蛋白質的性質，並使其凝結。微波消融治療已應用於不同的良性及惡性腫瘤並具有安全、微創、操作簡便、患者恢復快及併發症低等優點。部分類型的良性腫瘤可能通過稱爲癌症進展的過程轉變爲惡性腫瘤。根據弗若斯特沙利文資料，肺結節、甲狀腺結節及乳腺結節患者的癌症進展率分別爲5.5%、5.0%和7.0%。微波消融治療可以通過抑制良性腫瘤發展爲惡性腫瘤來阻止癌症進展。成立於","text":"微波消融醫療器械龍頭企業百德醫療，即將完成IPO最後衝刺。2022年9月22日，百德醫療（6678.HK）公告稱公司在香港資本市場開啓招股環節，保薦機構爲中泰國際融資、中銀國際亞洲。公司此次IPO預計發行2.48億股，其中香港公開發售2480萬股，國際發售2.23億股，超額配售最多爲3720萬股（如有）。發行價格區間爲每股1.40至1.72港元。預計上市日期爲2022年10月5日，每手2000股。募集資金中41%將用作擴大及深化公司的產品組合、升級公司的醫療許可證及擴充研發團隊；38%將用作選擇性尋求能夠補充公司的現有產品組合、銷售及分銷網絡、技術，併爲公司的業務增長創造協同效應的策略收購、投資或業務協同合作機會；8%將用作透過設立海外辦事處；3%將用於購買自動化機械及設備以提高公司的生產線的自動化水平；10%將用作額外營運資金及其他一般公司用途。目前看來，作爲國內市場上首家有甲狀腺3類證企業，公司已成爲微波消融醫療器械領先供應商之一，按2021年微波消融針的銷售收入及銷量計，更是中國治療甲狀腺結節及乳腺結節的微波消融醫療器械第一大龍頭，規模、技術優勢背景下公司近年來業績不斷增長。未來，隨着行業規模高速增長以及公司與機構合作的研發模式保證產品線穩定擴張，百德醫療有望持續展現高增長態勢。深耕微波消融 成就領域大龍頭地位十餘年專注，百德醫療已經成爲行業的龍頭型企業。微波消融是一種微創治療技術，利用微波能量產生的極高熱量改變腫瘤細胞蛋白質的性質，並使其凝結。微波消融治療已應用於不同的良性及惡性腫瘤並具有安全、微創、操作簡便、患者恢復快及併發症低等優點。部分類型的良性腫瘤可能通過稱爲癌症進展的過程轉變爲惡性腫瘤。根據弗若斯特沙利文資料，肺結節、甲狀腺結節及乳腺結節患者的癌症進展率分別爲5.5%、5.0%和7.0%。微波消融治療可以通過抑制良性腫瘤發展爲惡性腫瘤來阻止癌症進展。成立於","images":[{"img":"https://static.tigerbbs.com/ddf6f87a35f64a9154479fcab2f44543","width":"599","height":"262"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/661416943","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":9,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":368,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}